Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX101 and bevacizumab in metastatic renal cell carcinoma
NCT02187302Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jul 2014
- Primary completion
- Jul 2016
- Modality
- Polymer-based Nanoparticles
- Countries
- 2
01
Overview
A Phase 2 trial of CRLX101 in metastatic renal cell carcinoma (mRCC), sponsored by Lumos Pharma, Inc.. Started Jul 2014; status: completed.
02
Drugs
CRLX101
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT02187302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187302.